ICYMI: Patients with a Certain Genotype Are More Likely to Discontinue Imuran Due to Toxicity

  Dr. Cecilia Chung and associates at the Vanderbilt University’s Medical Center conducted a study published recently in MedPage Today. Results showed that patients who had inflammatory disorders, as well…

Continue Reading ICYMI: Patients with a Certain Genotype Are More Likely to Discontinue Imuran Due to Toxicity
Results From This Study are Encouraging for Alpha-1 Antitrypsin Deficiency Liver Disease
source: pixabay.com

Results From This Study are Encouraging for Alpha-1 Antitrypsin Deficiency Liver Disease

  Takeda and its collaborator, Arrowhead Pharmaceuticals, recently announced results from AROAAT-2002 of the investigational drug fazirsiran. The drug is an RNA interference therapeutic developed to lessen alpha-1 antitirypsin protein…

Continue Reading Results From This Study are Encouraging for Alpha-1 Antitrypsin Deficiency Liver Disease
Nebraskans for Medical Marijuana Are Running Out of Time to Put Petitions on the Ballot Before November
source: pixabay.com

Nebraskans for Medical Marijuana Are Running Out of Time to Put Petitions on the Ballot Before November

  As time runs out, volunteer Dominic Gillen is running even harder. In an interview with KETV, he admits that they are not yet where they should be in order…

Continue Reading Nebraskans for Medical Marijuana Are Running Out of Time to Put Petitions on the Ballot Before November
Azathioprine: Specific Genotype Linked to Treatment Discontinuation Due to Toxicity
source: pixabay.com

Azathioprine: Specific Genotype Linked to Treatment Discontinuation Due to Toxicity

According to a story from Medpage Today, patients using the drug azathioprine who carried a certain genotype were three times more likely to need to either cease treatment or reduce…

Continue Reading Azathioprine: Specific Genotype Linked to Treatment Discontinuation Due to Toxicity